FAIM
CATX icon

Financial Advocates Investment Management’s Perspective Therapeutics CATX Stock Holding History

Financial Advocates Investment Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,151
Closed -$5K – 504
2018
Q2 		$5K Hold
1,151
– – ﹤0.01% 486
2018
Q1 		$5K Buy
+1,151
New +$5.08K ﹤0.01% 483

Other funds holding CATX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CWM
Cahaba Wealth Management Atlanta, Georgia $1.66B AUM 17.04% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Financial Advocates Investment Management's CATX Position: Q3 2018 in Review

Financial Advocates Investment Management sold out of Perspective Therapeutics (CATX) in Q3 2018, closing a stake of 1,151 shares — an estimated $5K sold.

Financial Advocates Investment Management first reported a position in CATX in Q1 2018 and held it in 2 quarters. The position peaked at $5K in Q2 2018. 29 funds tracked by Wall St. Rank hold CATX as of Q3 2018.

  • Financial Advocates Investment Management reported no remaining Perspective Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Financial Advocates Investment Management sold 1,151 Perspective Therapeutics shares in Q3 2018, an estimated $5K.
  • Financial Advocates Investment Management first reported a position in Perspective Therapeutics in Q1 2018 and held it in 2 quarters.
  • Financial Advocates Investment Management's Perspective Therapeutics position peaked at $5K in Q2 2018.
  • 29 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2018.

Based on Financial Advocates Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.